IP Library › Granted Patent US 12,195,535
Granted Patent B2
US 12,195,535 · App. 18/162,991 · Granted Jan 14, 2025

Antibodies binding to VISTA at acidic pH

Inventors: Robert J. Johnston (San Mateo, CA); Arvind Rajpal (San Francisco, CA); Paul O. Sheppard (Granite Falls, WA); Luis Borges (Houston, TX); Andrew Rankin (Redwood City, CA); Keith Sadoon Bahjat (Woodside, CA); Alan J. Korman (Piedmont, CA); Andy X. Deng (Princeton, NJ); Lin Hui Su (Somerville, MA); Ginger Rakestraw (Somerville, MA)
Assignees: Five Prime Therapeutics, Inc.; Bristol-Myers Squibb Company
C07K16/2812C07K2317/34C07K2317/622C07K2317/732C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,535
App. No.
18/162,991
Granted
Jan 14, 2025
Kind
B2
Abstract

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Claims (37)

1. A nucleic acid comprising a polynucleotide sequence that encodes an antibody that specifically binds to human V-domain Ig Suppressor of T cell Activation (hVISTA), the antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (VH) comprising VH CDR1, CDR2 and CDR3, which comprise amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 11, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 39, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 83, SEQ ID NO: 79, SEQ ID NO: 87, SEQ ID NO: 193, SEQ ID NO: 201, SEQ ID NO: 197, SEQ ID NO: 213, SEQ ID NO: 185, SEQ ID NO: 237, SEQ ID NO: 257, SEQ ID NO: 245, SEQ ID NO: 241, SEQ ID NO: 269, SEQ ID NO: 289, SEQ ID NO: 273, SEQ ID NO: 285, SEQ ID NO: 265, SEQ ID NO: 301, SEQ ID NO: 293, SEQ ID NO: 313, SEQ ID NO: 277, or SEQ ID NO: 305; and wherein the light chain comprises a light chain variable region (VL) comprising VL CDR1, CDR2 and CDR3, which comprise amino acid positions 24-35, 51-57, and 90-98, respectively, of SEQ ID NO: 68.

2. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 11, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 39, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 83, SEQ ID NO: 79, SEQ ID NO: 87, SEQ ID NO: 193, SEQ ID NO: 201, SEQ ID NO: 197, SEQ ID NO: 213, SEQ ID NO: 185, SEQ ID NO: 237, SEQ ID NO: 257, SEQ ID NO: 245, SEQ ID NO: 241, SEQ ID NO: 269, SEQ ID NO: 289, SEQ ID NO: 273, SEQ ID NO: 285, SEQ ID NO: 265, SEQ ID NO: 301, SEQ ID NO: 293, SEQ ID NO: 313, SEQ ID NO: 277, or SEQ ID NO: 305.

3. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 15, SEQ ID NO: 51, SEQ ID NO: 11, SEQ ID NO: 55, SEQ ID NO: 59, SEQ ID NO: 39, SEQ ID NO: 63, SEQ ID NO: 71, SEQ ID NO: 75, SEQ ID NO: 83, SEQ ID NO: 79, or SEQ ID NO: 87, SEQ ID NO: 193, SEQ ID NO: 201, SEQ ID NO: 197, SEQ ID NO: 213, SEQ ID NO: 185, SEQ ID NO: 237, SEQ ID NO: 257, SEQ ID NO: 245, SEQ ID NO: 241, SEQ ID NO: 269, SEQ ID NO: 289, SEQ ID NO: 273, SEQ ID NO: 285, SEQ ID NO: 265, SEQ ID NO: 301, SEQ ID NO: 293, SEQ ID NO: 313, SEQ ID NO: 277, or SEQ ID NO: 305.

4. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VL comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 68.

5. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VL comprises the amino acid sequence of SEQ ID NO: 68.

6. The nucleic acid of claim 2 , wherein the polynucleotide sequence encodes an antibody wherein the VL comprises the amino acid sequence of SEQ ID NO: 68.

7. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises VH CDR1, CDR2 and CDR3 comprising the amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 55, and wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 55.

8. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 55.

9. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 55 and the VL comprises the amino acid sequence of SEQ ID NO: 68.

10. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises VH CDR1, CDR2 and CDR3 comprising the amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 51, and wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 51.

11. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 51.

12. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 51 and the VL comprises the amino acid sequence of SEQ ID NO: 68.

13. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody the VH comprises VH CDR1, CDR2 and CDR3 comprising the amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 11, and wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 11.

14. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 11.

15. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 11 and the VL comprises the amino acid sequence of SEQ ID NO: 68.

16. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises VH CDR1, CDR2 and CDR3 comprising the amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 15, and wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 15.

17. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 15.

18. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 15 and the VL comprises the amino acid sequence of SEQ ID NO: 68.

19. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises VH CDR1, CDR2 and CDR3 comprising the amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 39, and wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 39.

20. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 39.

21. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 39 and the VL comprises the amino acid sequence of SEQ ID NO: 68.

22. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises VH CDR1, CDR2 and CDR3 comprising the amino acid positions 26-35, 50-66, and 99-112, respectively, of SEQ ID NO: 59, and wherein the VH comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 59.

23. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 59.

24. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the VH comprises the amino acid sequence of SEQ ID NO: 59 and the VL comprises the amino acid sequence of SEQ ID NO: 68.

25. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the antibody binds to h VISTA in acidic pH conditions with a Kp of 10 −8 M or less, wherein acidic pH conditions are conditions having a pH of 6.0 to 6.5.

26. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the antibody does not detectably bind to h VISTA in physiological conditions as measured by surface plasmon resonance (SPR), wherein physiological conditions are conditions having a pH of 7.4.

27. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises a human IgG1, IgG2 or IgG4 heavy chain constant region.

28. The nucleic acid of claim 27 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises a human IgG4 heavy chain constant region comprising an S228P substitution, wherein S228 is numbered according to EU index.

29. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 163, 182, 183, or 184, optionally further comprising a C-terminal lysine residue.

30. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 163, 182, 183, or 184 and optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises a light chain constant region comprising the amino acid sequence of SEQ ID NO: 164.

31. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 163, optionally further comprising a C-terminal lysine residue.

32. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 57, optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 58.

33. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 13, optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 14.

34. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 17, optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 18.

35. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 41, optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 42.

36. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 53, optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 54.

37. The nucleic acid of claim 1 , wherein the polynucleotide sequence encodes an antibody wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 61, optionally further comprising a C-terminal lysine residue, and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 62.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2023
From: JOHNSTON, ROBERT J.; RAJPAL, ARVIND; KORMAN, ALAN J.; SHEPPARD, PAUL O.; BAHJAT, KEITH SADOON; DENG, ANDY X.; SU, LIN HUI; RAKESTRAW, GINGER
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 065104/0035 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2023
From: BORGES, LUIS; RANKIN, ANDREW
To: FIVE PRIME THERAPEUTICS, INC.
Reel/Frame 065104/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2023
From: BORGES, LUIS; RANKIN, ANDREW
To: FIVE PRIME THERAPEUTICS, INC.
Reel/Frame 063131/0095 →
Continuity (4)
Division 16493712
Provisional Application 62636746 · Feb 28, 2018
Provisional Application 62471196 · Mar 14, 2017
Related Publication 20240092907A1 · Mar 21, 2024
References Cited (154)
US 4997913A · Hellstrom et al. · 1991 [cited by applicant]
US 5827817A · Larsen et al. · 1998 [cited by applicant]
US 7833530B2 · Alvarez et al. · 2010 [cited by applicant]
US 8114968B2 · Devy et al. · 2012 [cited by applicant]
US 8889628B2 · Shaw · 2014 [cited by applicant]
US 10259866B2 · Nitsch et al. · 2019 [cited by applicant]
US 20050260711A1 · Datta et al. · 2005 [cited by applicant]
US 20100260765A1 · Barry et al. · 2010 [cited by applicant]
US 20100330078A1 · Bender et al. · 2010 [cited by applicant]
US 20110027278A1 · Noelle et al. · 2011 [cited by applicant]
US 20110081666A1 · Alvarez et al. · 2011 [cited by applicant]
US 20120100140A1 · Reyes et al. · 2012 [cited by applicant]
US 20120108455A1 · Kodandapani et al. · 2012 [cited by applicant]
US 20120148571A1 · Lasters et al. · 2012 [cited by applicant]
US 20140105912A1 · Noelle · 2014 [cited by applicant]
US 20140341920A1 · Noelle et al. · 2014 [cited by applicant]
US 20140378660A1 · Short et al. · 2014 [cited by applicant]
US 20150265703A1 · Herting et al. · 2015 [cited by applicant]
US 20150337053A1 · McCarthy et al. · 2015 [cited by applicant]
US 20160096891A1 · Chen et al. · 2016 [cited by applicant]
US 20160159927A1 · Molloy et al. · 2016 [cited by applicant]
US 20160176963A1 · Maurer et al. · 2016 [cited by applicant]
US 20160347814A1 · Levine et al. · 2016 [cited by applicant]
US 20160347849A1 · Cai et al. · 2016 [cited by applicant]
US 20170051061A1 · Snyder et al. · 2017 [cited by applicant]
US 20170119877A1 · Green et al. · 2017 [cited by applicant]
US 20170198052A1 · Lin et al. · 2017 [cited by applicant]
US 20190330364A1 · Johnston et al. · 2019 [cited by applicant]
US 20200055936A1 · Johnston et al. · 2020 [cited by applicant]
US 20210017283A1 · Johnston et al. · 2021 [cited by applicant]
CN 104968364A · 2015 [cited by applicant]
CN 105246507A · 2016 [cited by applicant]
CN 106414489A · 2017 [cited by applicant]
CN 110563843A · 2019 [cited by applicant]
EP 2291536A4 · 2013 [cited by applicant]
RU 2550262C1 · 2015 [cited by applicant]
TW 201619195A · 2016 [cited by applicant]
WO 9201718A2 · 1992 [cited by applicant]
WO 9410309A1 · 1994 [cited by applicant]
WO 9411498A1 · 1994 [cited by applicant]
WO 9506118A1 · 1995 [cited by applicant]
WO 9530001A2 · 1995 [cited by applicant]
WO 9706176A2 · 1997 [cited by applicant]
WO 1997009068A2 · 1997 [cited by applicant]
WO 9808949A1 · 1998 [cited by applicant]
WO 9931117A1 · 1999 [cited by applicant]
WO 0000610A2 · 2000 [cited by applicant]
WO 2000012708A2 · 2000 [cited by applicant]
WO 2000078961A1 · 2000 [cited by applicant]
WO 0104297A2 · 2001 [cited by applicant]
WO 0173028A2 · 2001 [cited by applicant]
WO 2003105757A2 · 2003 [cited by applicant]
WO 2004022594A2 · 2004 [cited by applicant]
WO 2003013603 · 2004 [cited by applicant]
WO 2005027831A2 · 2005 [cited by applicant]
WO 2005110475A2 · 2005 [cited by applicant]
WO 2006012232A1 · 2006 [cited by applicant]
WO 2006116181A2 · 2006 [cited by applicant]
WO 2007033959A2 · 2007 [cited by applicant]
WO 2007067984A2 · 2007 [cited by applicant]
WO 2007100211A1 · 2007 [cited by applicant]
WO 2009140623A2 · 2009 [cited by applicant]
WO 2010104821A1 · 2010 [cited by applicant]
WO 2011120013A2 · 2011 [cited by applicant]
WO 2005110456 · 2012 [cited by applicant]
WO 2012033953A1 · 2012 [cited by applicant]
WO 2012174001A1 · 2012 [cited by applicant]
WO 2013082200A1 · 2013 [cited by applicant]
WO 2013134743A1 · 2013 [cited by applicant]
WO 2013192504A1 · 2013 [cited by applicant]
WO 2014039983A1 · 2014 [cited by applicant]
WO 2014089113A1 · 2014 [cited by applicant]
WO 2014190356A2 · 2014 [cited by applicant]
WO 2014197849A2 · 2014 [cited by applicant]
WO 2015069770A1 · 2015 [cited by applicant]
WO 2015097536A2 · 2015 [cited by applicant]
WO 2015109340A2 · 2015 [cited by applicant]
WO 2015187359A1 · 2015 [cited by applicant]
WO 2015191881A2 · 2015 [cited by applicant]
WO 2016007653A2 · 2016 [cited by applicant]
WO 2016090347A1 · 2016 [cited by applicant]
WO 2016094837A2 · 2016 [cited by applicant]
WO 2016207717A1 · 2016 [cited by applicant]
WO 2017078839A1 · 2017 [cited by applicant]
WO 2017120534A1 · 2017 [cited by applicant]
WO 2017137830A1 · 2017 [cited by applicant]
WO 2017175058A1 · 2017 [cited by applicant]
WO 2017181109A1 · 2017 [cited by applicant]
WO 2017181139A2 · 2017 [cited by applicant]
WO 2018027042A1 · 2018 [cited by applicant]
WO 2018047143A1 · 2018 [cited by applicant]
WO 2018132476A1 · 2018 [cited by applicant]
WO 2018169993A1 · 2018 [cited by applicant]
WO 2018195772A1 · 2018 [cited by applicant]
WO 2018237287A1 · 2018 [cited by applicant]
WO 2019078699A2 · 2019 [cited by applicant]
WO 2019087092A1 · 2019 [cited by applicant]
WO 2019165233A1 · 2019 [cited by applicant]
WO 2019183040A1 · 2019 [cited by applicant]
WO 2019185163A1 · 2019 [cited by applicant]
WO 2019185879A1 · 2019 [cited by applicant]
WO 2020014327A2 · 2020 [cited by applicant]
GenBank AAA53000.1, immunoglobin heavy chain, partial, Jul. 26, 2016, 4 pages. [cited by applicant]
GenBank ABF83385.1, circulating B cell antibody heavy chain variable region, partial, Jul. 14, 2016, 4 pages. [cited by applicant]
Machine translation of RU2550262, May 10, 2015, Pigareva et al., 10 pages. [cited by applicant]
PIR: S23628, Ig kappa chain V region—human (fragment), Jan. 21, 2000, 2 pages. [cited by applicant]
File History of U.S. Appl. No. 18/543,912, filed Dec. 18, 2023, Inventors: Robert J. Johnston et al., available on Patent Center. [cited by applicant]
Liu, “Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins,” Protein Cell, 2018, 9(1):15-32. [cited by applicant]
Almagaro et al., “Humanization of Antibodies,” Frontiers in Bioscience, 2008, 13:1619-1633. [cited by applicant]
Casset et al., “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design,” Biochem. and Biophys. Res. Comm., 2003, 307:198-205. [cited by applicant]
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” J. Mol. Biol., 1999, 293:865-881. [cited by applicant]
De Pascalis et al., “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” … [cited by applicant]
Lamminmaki et al., “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol,” J. Biol. Chem., 2001, 276(39): 36687-36694. [cited by applicant]
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 1996, 262:732-745. [cited by applicant]
Padlan et al., “Structure of an antibody-antigen complex: Crystal Structure of the HyHEL-10 Fab-lysozyme complex,” Proc. Natl. Acad. Sci. USA, 1989, 86:5938-5942. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. USA, 1982, 79:1979-1983. [cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning of Mutagenesis,” J. Mol. Biol., 2002, 320:415-428. [cited by applicant]
Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J. Mol. Biol., 1999, 294:151-162. [cited by applicant]
Lobo et al., “Antibody Pharmacokinetics and Pharmacodynamics”. J Pharm Sci., 2004; 93(11):2645-68. [cited by applicant]
Bostrom et al., “Improving Antibody Binding Affinity and Specificity for Therapeutic Development,” Methods Mol. Biol., 2009, 525:353-376. [cited by applicant]
Brown et al., “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody Vh CDR2: A Means of Minimizing B Cell Wastage from Somatic Hypermutation?,” J Immunol, 1996, 156:3285-3291. [cited by applicant]
Deng et al, “A New VISTA on combination therapy for negative checkpoint regulator blockade,” J Immunotherapy Cancer, 2016, 4(1):1-7. [cited by applicant]
Extended European Search Report received in European Patent Application No. 18738529.9 dated Jul. 3, 2020, Applicant: Bristol-Myers Squibb Company, 7 pages. [cited by applicant]
File History of U.S. Appl. No. 16/476,814, filed Jul. 9, 2019, Inventors: Robert J. Johnston et al. [cited by applicant]
File History of U.S. Appl. No. 16/493,712, filed Sep. 12, 2019, Inventors: Robert J. Johnston et al. [cited by applicant]
File History of U.S. Appl. No. 16/982,277, filed Sep. 18, 2020, Inventors: Robert J. Johnston et al. [cited by applicant]
File History of U.S. Appl. No. 17/258,866, filed Jan. 8, 2021, Inventors: Robert J. Johnston et al. [cited by applicant]
File History of U.S. Appl. No. 17/695,081, filed Mar. 15, 2022, Inventors: Robert J. Johnston et al. [cited by applicant]
File History of U.S. Appl. No. 17/761,458, filed Mar. 17, 2022, Inventors: Lin Hui Su et al. [cited by applicant]
Gonzales et al., “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumour Biol, 2005, 26(1):31-43. [cited by applicant]
International Search Report and Written Opinion for PCT/US2019/041154, dated Jan. 24, 2020, Applicant: Five Prime Therapeutics, Inc.; 21 pages. [cited by applicant]
International Search Report and Written Opinion for PCT/US2020/051421, dated Mar. 11, 2021, Applicant: Bristol-Myers Squibb Company, 30 pages. [cited by applicant]
International Search Report for PCT/US2018/013171, dated May 14, 2018, Applicant: Bristol-Myers Squibb Company, 16 pages. [cited by applicant]
International Search Report for PCT/US2018/022230, dated May 31, 2018, Applicant: Five Prime Therapeutics, Inc., 21 pages. [cited by applicant]
International Search Report for PCT/US2019/022895, dated Jul. 16, 2019, Applicant: Five Prime Therapeutics, Inc.; 14 pages. [cited by applicant]
Johnston et al., “Acidic pH Selective Binding of VISTA to PSGL-1 and Anti-Tumor Activity of Combined VISTA and PD-1 Blockade,” Cancer Research, 2019, 70(13): supplement. [cited by applicant]
Johnston et al., “VISTA is an Acidic pH-Selective Ligand for PSGL-1,” Nature, 2019, 574:565-588. [cited by applicant]
Krieg et al., “Functional Analysis of B and T Lymphocyte Attenuator engagement on CD4+ and CD8+ T Cells,” J Immunology, 2005, 175(10):6420-6427. [cited by applicant]
Kunik et al, “Structural Consensus among Antibodies Defines the Antigen Binding Site,” PLoS Comput Biol, 2012, 8(2):e1002388, 12 pages. [cited by applicant]
Le Mercier et al., “VISTA Regulates the Development of Protective Antitumor Immunity,” Cancer Res., 2014, 74(7):1933-1944. [cited by applicant]
Lenter et al., “Monospecific and Common Glycoprotein Ligands for E- and P-Selectin on Myeloid Cells,” J. Cell Biol., 1994, 125(2):471-481. [cited by applicant]
Lines et al., “VISTA is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy,” Cancer Immunol Res., 2014, 2(6):510-517. [cited by applicant]
Machine Translation of CN110563843A. [cited by applicant]
Machine Translation of WO 2019/078699, 41 pages. [cited by applicant]
Mahoney et al., “Acidity Changes Immunology: A New VISTA Pathway,” Nature Immunology, 2020, 21:13-16. [cited by applicant]
Mangsbo et al., “The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity,” Clin Cancer Res, 2015, 21(5):1115-26. [cited by applicant]
Matsumoto et al., “P-Selectin Glycoprotein Ligand-1 Negatively Regulates T-Cell Immune Responses,” J Immunol, 2009, 183:7204-7211. [cited by applicant]
Morris, “Epitope Mapping of Protein Antigens by Competition ELISA”, The Protein Protocols Handbook, Totowa, NJ, Humana Press, 1996, pp. 595-600. [cited by applicant]
Supplementary Extended European Search Report received in European Patent Application No. 18767615.0 dated Apr. 29, 2021, 12 pages. [cited by applicant]
Tinoco et al., “PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion,” Immunity, 2016, 44:1190-1203. [cited by applicant]
Wang et al., “VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses,” J. Exp. Med., 2011, 208(3):577-592. [cited by applicant]
Wark et al., “Latest Technologies for the Enhancement of Antibody Affinity,” Adv Drug Delivery Rev, 2006, 58(5-6):657-670. [cited by applicant]
Zhao et al., “Oncogenic Pathways that Affect Antitumor Immune Response and Immune Checkpoint Blockade Therapy,” Pharmacology & Therapeutics, 2018, 181:76-84. [cited by applicant]
Zhu et al., “B7-H5 costimulates human T cells via CD28H,” Nature Comm, 2013, 4:1-12. [cited by applicant]